Viridian Therapeutics GAAP EPS of -$0.34 beats by $0.68, revenue of $70.57M

* Viridian Therapeutics press release [https://seekingalpha.com/pr/20293955-viridian-therapeutics-reports-third-quarter-2025-financial-results-and-highlights-recent] (VRDN [https://seekingalpha.com/symbol/VRDN]): Q3 GAAP EPS of -$0.34 beats by $0.68.
* Revenue of $70.57M.

MORE ON VIRIDIAN THERAPEUTICS

* Viridian Therapeutics: De-Risked Leadership In Thyroid Eye Disease [https://seekingalpha.com/article/4826195-viridian-therapeutics-de-risked-leadership-in-thyroid-eye-disease]
* Viridian Therapeutics prices $251M share offering [https://seekingalpha.com/news/4506468-viridian-therapeutics-prices-251m-share-offering]
* Viridian Therapeutics announces proposed underwritten public offering [https://seekingalpha.com/news/4506331-viridian-therapeutics-announces-proposed-underwritten-public-offering]
* Seeking Alpha’s Quant Rating on Viridian Therapeutics [https://seekingalpha.com/symbol/VRDN/ratings/quant-ratings]
* Historical earnings data for Viridian Therapeutics [https://seekingalpha.com/symbol/VRDN/earnings]